Abstract:Rationale: Pyrrolidone-based drugs find widespread use in treating conditions such as epilepsy and Alzheimer's disease, and in various other medical applications. Brivaracetam, the latest generation of pyrrolidone drugs, has exhibited significant promise owing to chemical structure modifications. Its affinity to the SV2A receptor is double that of the previous-generation drug, levetiracetam. Consequently, brivaracetam holds substantial potential for diverse applications. As a novel drug not yet included in the pharmacopeias of developed nations, comprehensive analysis and research are necessary to guarantee its safe utilization in clinical settings. Methods: A liquid chromatography quadrupole time-of-flight tandem mass spectrometry (LC/QTOFMS) method has been developed to effectively separate, identify and characterize both the degradation products and process-related substances of brivaracetam. Stress testing of the sample was carried out following the guidelines outlined in ICH Q1A(R2). The structures of these impurities were identified through positive electrospray ionization QTOF high-resolution MS and NMR spectroscopy. Additionally, the formation mechanism of each degradation product is thoroughly discussed. Results: Under the analytical conditions outlined in this paper, brivaracetam and its degradation products were effectively separated. Thirteen degradation products were detected and characterized, shedding light on their origins and degradation pathways. Among these, three degradation products align with previously reported impurities, and two unreported degradation products were synthesized and confirmed through NMR spectroscopy. The stress testing results revealed the instability of brivaracetam under acidic, alkaline, oxidative and thermal stress conditions, while it exhibited relative stability under photolytic stress conditions. Conclusion: The study developed an analytical method for brivaracetam that enabled the effective detection and separation of brivaracetam and its 13 degradation products. This method addresses a gap in both current domestic and foreign drug standards. The structures of all the major degradation products were characterized by high-resolution LC/QTOFMS, which is essential for quality control during the drug production process, stability evaluation and the establishment of proper storage conditions.

Identification and Characterization of Four Process-Related Impurities in Retigabine

Identification and synthesis of potential process-related impurities of trametinib: an anti-cancer drug

Identification, Characterization, And Synthesis Of Process-Related Impurities In Antiproliferative Agent Tq-B3203

Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique.

Identification of degradation products of brivaracetam using liquid chromatography quadrupole time-of-flight tandem mass spectrometry: Degradation pathway elucidation

Isolation and Structural Elucidation of an Unknown Impurity in Prasugrel by Semi-Preparative Liquid Chromatography.

Identification of undescribed key impurities of homoharringtonine bulk drug

Isolation, structural characterization and quality control strategy of an unknown process-related impurity in sugammadex sodium

Isolation and identification of four major impurities in capreomycin sulfate.

Identification and Synthesis of Oxidative-Degradation and Starting Materials-Attributed Impurities in Lisdexamfetamine Dimesylate

Identification of a New Retigabine Derivative with Improved Photostability for Selective Activation of Neuronal Kv7 Channels and Antiseizure Activity.

Identification and quantitative analysis of genotoxic impurities in rifampicin: Development and validation of a targeted LC-MS/MS method for 1-amino-4-methylpiperazine

Characterization of Elvitegravir and Its Related Impurities Using ESI–LC–MS, NMR Techniques, Method Development and Validation of Its Related Substances by HPLC Method

Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate

Detection, identification, characterization, and high-performance liquid chromatography quantification of five impurities from a methazolamide product

Synthesis and Characterization of Impurities of Barnidipine Hydrochloride, an Antihypertensive Drug Substance

Determination of Four Kinds of Antiepileptic Drugs Concentration in Human Brain Tissue by HPLC

Characterization of Impurities in the Bulk Drug Lisinopril by Liquid Chromatography/ion Trap Spectrometry

Isolation, identification, and characterization of potential impurities of doramectin and evaluation of their insecticidal activity

An innovative impurity profiling of esmolol hydrochloride injection using UPLC-MS based multiple mass defect filter, chemometrics and in-silico toxicity prediction

Structurally related impurity profiling of thiacloprid by orbitrap and de novo identification tool